Bisphosphonate-induced osteonecrosis of the jaws: Prospective study of 80 patients with multiple myeloma and other malignancies
- 30 September 2008
- journal article
- Published by Elsevier BV in Oral Oncology
- Vol. 44 (9), 857-869
- https://doi.org/10.1016/j.oraloncology.2007.11.012
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- Breast Cancer: Bisphosphonate Therapy for Metastatic Bone DiseaseClinical Cancer Research, 2006
- Myeloma bone disease and treatment optionsEuropean Journal Of Cancer, 2006
- Guidelines on the diagnosis and management of multiple myeloma 2005British Journal of Haematology, 2006
- Zoledronate inhibits proliferation and induces apoptosis of imatinib-resistant chronic myeloid leukaemia cellsLeukemia, 2005
- Hypercalcemia Associated with CancerNew England Journal of Medicine, 2005
- Bisphosphonates and CancerJournal of Veterinary Internal Medicine, 2004
- Bisphosphonates: Preclinical ReviewThe Oncologist, 2004
- Aetiology of bone disease and the role of bisphosphonates in multiple myelomaThe Lancet Oncology, 2003
- Bisphosphonates: an overview with special reference to alendronateAnnals of Clinical Biochemistry: International Journal of Laboratory Medicine, 2001
- Zoledronate Is a Potent Inhibitor of Myeloma Cell Growth and Secretion of IL-6 and MMP-1 by the Tumoral EnvironmentJournal of Bone and Mineral Research, 1999